Since our data demonstrated that lipin-1 silencing sensitizes prostate and breast cancer cells to rapamycin, we then verified whether pharmacological inhibition of lipins activity could be considered as a potential therapeutic option or not. Here, LPIN1 is linked to breast cancer.